172 related articles for article (PubMed ID: 28827765)
1. Opposite feedback from mTORC1 to H-ras and K-ras4B downstream of SREBP1.
Posada IMD; Lectez B; Siddiqui FA; Oetken-Lindholm C; Sharma M; Abankwa D
Sci Rep; 2017 Aug; 7(1):8944. PubMed ID: 28827765
[TBL] [Abstract][Full Text] [Related]
2. Oncogenic PI3K and K-Ras stimulate de novo lipid synthesis through mTORC1 and SREBP.
Ricoult SJ; Yecies JL; Ben-Sahra I; Manning BD
Oncogene; 2016 Mar; 35(10):1250-60. PubMed ID: 26028026
[TBL] [Abstract][Full Text] [Related]
3. Oncogenic KRAS signaling activates mTORC1 through COUP-TFII-mediated lactate production.
Byun JK; Park M; Yun JW; Lee J; Kim JS; Cho SJ; Lee YM; Lee IK; Choi YK; Park KG
EMBO Rep; 2019 Jun; 20(6):. PubMed ID: 30988000
[TBL] [Abstract][Full Text] [Related]
4. mTORC1 suppresses PIM3 expression via miR-33 encoded by the SREBP loci.
Kelsey I; Zbinden M; Byles V; Torrence M; Manning BD
Sci Rep; 2017 Nov; 7(1):16112. PubMed ID: 29170467
[TBL] [Abstract][Full Text] [Related]
5. SPRED1 Interferes with K-ras but Not H-ras Membrane Anchorage and Signaling.
Siljamäki E; Abankwa D
Mol Cell Biol; 2016 Oct; 36(20):2612-25. PubMed ID: 27503857
[TBL] [Abstract][Full Text] [Related]
6. Rapalogs can promote cancer cell stemness in vitro in a Galectin-1 and H-ras-dependent manner.
Posada IMD; Lectez B; Sharma M; Oetken-Lindholm C; Yetukuri L; Zhou Y; Aittokallio T; Abankwa D
Oncotarget; 2017 Jul; 8(27):44550-44566. PubMed ID: 28562352
[TBL] [Abstract][Full Text] [Related]
7. Discrete signaling mechanisms of mTORC1 and mTORC2: Connected yet apart in cellular and molecular aspects.
Jhanwar-Uniyal M; Amin AG; Cooper JB; Das K; Schmidt MH; Murali R
Adv Biol Regul; 2017 May; 64():39-48. PubMed ID: 28189457
[TBL] [Abstract][Full Text] [Related]
8. Principles of K-Ras effector organization and the role of oncogenic K-Ras in cancer initiation through G1 cell cycle deregulation.
Nussinov R; Tsai CJ; Muratcioglu S; Jang H; Gursoy A; Keskin O
Expert Rev Proteomics; 2015; 12(6):669-82. PubMed ID: 26496174
[TBL] [Abstract][Full Text] [Related]
9. Impact of Nrf2 on tumour growth and drug sensitivity in oncogenic K-ras-transformed cells in vitro and in vivo.
Shao J; Glorieux C; Liao J; Chen P; Lu W; Liang Z; Wen S; Hu Y; Huang P
Free Radic Res; 2018 Jun; 52(6):661-671. PubMed ID: 29621903
[TBL] [Abstract][Full Text] [Related]
10. Phenotypic Screening Identifies Protein Synthesis Inhibitors as H-Ras-Nanocluster-Increasing Tumor Growth Inducers.
Najumudeen AK; Posada IM; Lectez B; Zhou Y; Landor SK; Fallarero A; Vuorela P; Hancock J; Abankwa D
Biochemistry; 2015 Dec; 54(49):7212-21. PubMed ID: 26568031
[TBL] [Abstract][Full Text] [Related]
11. mTORC1 Signaling: A Double-Edged Sword in Diabetic β Cells.
Ardestani A; Lupse B; Kido Y; Leibowitz G; Maedler K
Cell Metab; 2018 Feb; 27(2):314-331. PubMed ID: 29275961
[TBL] [Abstract][Full Text] [Related]
12. mTORC1 and Nutrient Homeostasis: The Central Role of the Lysosome.
Rabanal-Ruiz Y; Korolchuk VI
Int J Mol Sci; 2018 Mar; 19(3):. PubMed ID: 29534520
[TBL] [Abstract][Full Text] [Related]
13. ASPP2 Is a Novel Pan-Ras Nanocluster Scaffold.
Posada IM; Serulla M; Zhou Y; Oetken-Lindholm C; Abankwa D; Lectez B
PLoS One; 2016; 11(7):e0159677. PubMed ID: 27437940
[TBL] [Abstract][Full Text] [Related]
14. Genetic ablation of S6-kinase does not prevent processing of SREBP1.
Lewis CA; Griffiths B; Santos CR; Pende M; Schulze A
Adv Enzyme Regul; 2011; 51(1):280-90. PubMed ID: 21093473
[TBL] [Abstract][Full Text] [Related]
15. Proto-oncogenic H-Ras, K-Ras, and N-Ras are involved in muscle differentiation via phosphatidylinositol 3-kinase.
Lee J; Choi KJ; Lim MJ; Hong F; Choi TG; Tak E; Lee S; Kim YJ; Chang SG; Cho JM; Ha J; Kim SS
Cell Res; 2010 Aug; 20(8):919-34. PubMed ID: 20603646
[TBL] [Abstract][Full Text] [Related]
16. Membrane-mediated induction and sorting of K-Ras microdomain signaling platforms.
Weise K; Kapoor S; Denter C; Nikolaus J; Opitz N; Koch S; Triola G; Herrmann A; Waldmann H; Winter R
J Am Chem Soc; 2011 Feb; 133(4):880-7. PubMed ID: 21141956
[TBL] [Abstract][Full Text] [Related]
17. Functional interactions of Raf and MEK with Jun-N-terminal kinase (JNK) result in a positive feedback loop on the oncogenic Ras signaling pathway.
Adler V; Qu Y; Smith SJ; Izotova L; Pestka S; Kung HF; Lin M; Friedman FK; Chie L; Chung D; Boutjdir M; Pincus MR
Biochemistry; 2005 Aug; 44(32):10784-95. PubMed ID: 16086581
[TBL] [Abstract][Full Text] [Related]
18. Cryptotanshinone activates AMPK-TSC2 axis leading to inhibition of mTORC1 signaling in cancer cells.
Chen W; Pan Y; Wang S; Liu Y; Chen G; Zhou L; Ni W; Wang A; Lu Y
BMC Cancer; 2017 Jan; 17(1):34. PubMed ID: 28061838
[TBL] [Abstract][Full Text] [Related]
19. mTORC1 and IRS1: Another Deadly Kiss.
Ardestani A; Maedler K
Trends Endocrinol Metab; 2018 Nov; 29(11):737-739. PubMed ID: 30082207
[TBL] [Abstract][Full Text] [Related]
20. Molecular logic of mTORC1 signalling as a metabolic rheostat.
Valvezan AJ; Manning BD
Nat Metab; 2019 Mar; 1(3):321-333. PubMed ID: 32694720
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
